Santhera Pharmaceuticals Holding AG SANN

SWX: SANN | ISIN: CH0027148649   5/05/2025
14,52 CHF (-1,09%)
(-1,09%)   5/05/2025

29 april 2025 · Santhera Publishes Agenda for its Annual General Meeting · Persbericht

29 april 2025 · Santhera Full Year Results for the Year Ended 31 December 2024 · Persbericht

16 april 2025 · Santhera shares updates on commercial rollout of AGAMREE® · Persbericht

27 maart 2025 · Santhera proposes Dr. Melanie Rolli as new member of Board of Directors · Persbericht

24 maart 2025 · Santhera to share latest on commercial rollout of AGAMREE® and future strategic priorities at Capital Markets Day · Persbericht

4 maart 2025 · Full Year Trading Update · Persbericht

13 februari 2025 · Santhera Announces Agreement with German GKV-SV on Reimbursement Amount for AGAMREE® (vamorolone) for the Treatment of Duchenne Muscular Dystrophy in Germany · Persbericht

10 februari 2025 · Santhera Announces Chief Financial Officer Transition with Appointment of Catherine Isted · Persbericht

16 januari 2025 · Santhera Receives Positive NICE Final Guidance for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy · Persbericht

16 januari 2025 · Santhera Pharmaceuticals Provides Update on Royalty Agreement for AGAMREE® (Vamorolone) and Warrants held by Idorsia · Persbericht

14 januari 2025 · Santhera Receives Positive Recommendation from Scottish Medicines Consortium for the Use of AGAMREE® (Vamorolone) in Duchenne Muscular Dystrophy Patients in NHS Scotland · Persbericht

6 januari 2025 · Santhera Enters into Supply and Distribution Agreement for AGAMREE® (Vamorolone) with Clinigen Group · Persbericht

20 december 2024 · Santhera Announces Approval in Hong Kong for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy · Persbericht

11 december 2024 · Santhera Announces Approval from China’s NMPA for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy · Persbericht

10 december 2024 · Santhera Receives Positive Recommendation from NICE for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy · Persbericht

12 november 2024 · Santhera Enters into Exclusive Supply Agreement for AGAMREE® (Vamorolone) with Ali Al Suwaidi Trading Establishment (ASTE) in Qatar · Persbericht

1 oktober 2024 · Santhera Announces Positive Topline Results from LIONHEART Study with AGAMREE® (vamorolone) Demonstrating Unique Mineralocorticoid Receptor Antagonism · Persbericht

24 september 2024 · Santhera Announces Acceptance by Swissmedic of Marketing Authorization Application for AGAMREE® (vamorolone) in Duchenne Muscular Dystrophy · Persbericht

12 september 2024 · Santhera Announces Half-Year 2024 Financial Results and Provides Corporate Update · Persbericht

10 september 2024 · Santhera Enters into an Exclusive Distribution Agreement with GENESIS Pharma for AGAMREE® (Vamorolone) in Central and Eastern Europe · Persbericht

Mijn selecties